|
Jun 2
|
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
|
|
May 6
|
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer
|
|
May 6
|
Bluebird pleads for deal support; Unity, Mersana lay off staff
|
|
Apr 23
|
Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting
|
|
Feb 24
|
Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025
|